July 15, 2022
A California federal judge on Friday granted $9.9 million in attorney fees and gave final approval to a $33 million settlement that resolves claims that generic-drug maker Impax Laboratories Inc. failed to disclose a federal investigation over possibly collusive market activity.
August 02, 2021
A proposed class of Impax Laboratories Inc. investors asked a California federal judge to preliminarily approve a $33 million settlement that would resolve claims the generic-drug maker failed to disclose a federal investigation over possibly collusive market activity.
August 12, 2019
A California federal judge on Monday again dismissed a shareholder suit alleging generic-drug maker Impax Laboratories Inc. failed to disclose to investors a federal investigation over possibly collusive market activity, finding the shareholders failed to remedy the issues that got their complaint tossed the first time around.
December 07, 2018
Impax Laboratories has asked a California federal judge to again quash investors' attempt to revive claims that the generic-drug manufacturer hid news of a federal investigation into whether it was colluding with its competitors to fix the prices of two generic drugs, saying the latest complaint still misses the mark.
September 07, 2018
A California federal judge on Friday dismissed a shareholder suit alleging generic-drug maker Impax Laboratories Inc. failed to disclose to investors a federal investigation over possibly collusive market activity, but also threw investors a life jacket, saying it's possible they could allege a scheme if they can elaborate how executives allegedly fixed prices.